Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 1 of 40 PageID #:3359
`Case: 1:16-cv—00651 Document #: 114-5 Filed: 06/25/18 Page 1 of 40 PageID #:3359
`
`SECTION III-C
`
`SECTION III-C
`
`

`

`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 2 of 40 PageID #:3360
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (N.D. Ill.)
`Freseinus Kabi’s Exhibit List
`Description
`FK-DEXMED0197968- US Patent 4,544,664 [Karjalainen et al.] (10.01.1985) ['664 patent]
`
`Bates
`
`FK-DEXMED0197981
`
`FK-DEXMED 0005897
`
`FK-DEXMED 0005895- US Patent 5,344,840 [Maze et al.] (09.06.1994) ['840 patent]
`
`US Patent 5,716,988 [Ibrahim et al.] (1998.02.10) ['988 patent]
`
`FK-DEXMED 0196063- US Patent 5,817,332 [Urtti et al.] (10.06.1998) ['332 patent]
`
`
`FK-DEXMED 0196070
`
`FK-DEXMED 0005855- US 2008/0308444 A1 [McClain et al.] (12.18.2008)
`
`
`FK-DEXMED 0005863
`
`FK-DEXMED 0005864- US 2010/0197694 A1 [Horn] (08.05.2010) [Horn I]
`
`
`FK-DEXMED 0005875
`
`FK-DEXMED 0005876- US 2011/0152271 A1 [Horn] (06.23.2011) [Horn II]
`
`
`FK-DEXMED 0005882
`
`FK-DEXMED 0005883- US 2011/0230534 A1 [Miyawaki et al.] (09.22.2011)
`
`
`FK-DEXMED 0005894
`
`US 2010/0041769 A1 [Pacheco et al.] (02.18.2010)
`
`FK-DEXMED0197608- UK Patent Application GB 2101114 A [Karjalainen] (1983.01.12)
`FK-DEXMED0197631
`
`Exhibit 2 Documents Considered by Andrew W. Carter
`Carter Exhibit 4.1 Graph of Precedex™ Premix Annual Vial Sales (In Millions): 2013-2017 [1]
`Carter Exhibit 4.2 Summary of Precedex™ Premix Net Vial Sales [1]
`Carter Exhibit 4.3 Graph of Precedex™ Premix Annual Net Sales (In Millions): 2013-2017 [1] [2]
`Carter Exhibit 4.4 Calculation of Precedex™ Premix Annual Net Sales [1]
`
`Plaintiff's Objections
`F, H, P, R
`
`F, H, P
`
`F, H, P, R
`
`F, H, P
`
`F, H, P, R
`
`F, H, P, R
`
`F, H, P, R
`
`F, H, P, R
`
`F, H, P, R
`F, H, P
`
`H
`H
`H
`H
`H
`
`DTX
`001
`
`002
`
`003
`
`004
`
`005
`
`006
`
`007
`
`008
`
`009
`010
`
`011
`012
`013
`014
`015
`
`1
`
`

`

`Bates
`
`HOSPIRA_02501949-
`HOSPIRA_02501966
`
`HOSPIRA_02501941-
`HOSPIRA_02501948
`
`DTX
`016
`
`017
`
`018
`
`019
`
`020
`
`021
`
`022
`023
`024
`025
`
`026
`027
`
`028
`029
`
`030
`
`031
`032
`033
`
`034
`
`035
`
`036
`
`037
`038
`039
`040
`041
`
`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 3 of 40 PageID #:3361
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Carter Exhibit 5.1 Calculation of Precedex™ Premix Off-Invoice Discounts, Cost of Sales and Gross Profit:
`2013-2017
`Carter Exhibit 5.2 Calculation of Precedex™ Premix Off-Invoice Discounts, Cost of Sales and Gross Profit
`Per Vial: 2015 - 2017
`Carter Exhibit 6.1 Graph of Dexmedetomidine Annual Equivalent Vial Sales (In Millions) and Precedex™
`Premix Market Share: 2000-2017 [1] [2]
`Carter Exhibit 6.2 Dexmedetomidine Annual Equivalent Vial Sales and Dexmedetomidine Market Share:
`2000-2017 [1] [2]
`Carter Exhibit 6.3 Graph of Dexmedetomidine Annual Sales (In Millions) and Precedex™ Premix Market
`Share: 2000-2017 [1] [2]
`Carter Exhibit 6.4 Dexmedetomidine Annual Sales Per Ims Health And Market Share (In Millions): 2000-
`2017 [1] [2]
`Carter Exhibit 7.1 Graph of IV Sedatives Annual Average Price Per Vial: 2000 - 2017 [1] [2]
`Carter Exhibit 7.2 Calculation of Injectable Sedative Market Price Per Unit: Q4 2000-Q4 2017 [1]
`Carter Exhibit 7.3 Summary of Precedex™ Premix Vial Sales: Q4 2000-Q4 2017 [1]
`Carter Exhibit 8.1 Calculation of Potential Additional Profit Hospira Would Have Realized Had It Introduced
`Precedex™ Premix in 2000: Q4 2000- Q2 2014
`Carter Exhibit 8.2 Calculation of Potential Premix Price Per Vial
`Carter Exhibit 8.3 Calculation of Average Price Premium of Precedex™ Premix Over Concentrate: 2015-
`2017 [1]
`Carter Exhibit 8.4 Calculation of Precedex™ Gross Profit: Q4 2000 - Q2 2014 [1]
`Carter Carter Exhibit 8.5 Calculation of Precedex™ Concentrate Profit Margin for the Period Jan. 2012
`through June 2014 [1] [2]
`Carter Exhibit 8.6 Calculation of Average Precedex™ Premix Market Share in the Injectable Sedative
`Market [1]
`Carter Exhibit 9.1 Summary of ICU Sedation and Procedural Sedation Market
`Carter Exhibit 9.2 Summary of Other Patent Claims Covering Dexmedetomidine
`2018.02.22 [D.I. 1] Complaint for Declaratory Judgment, Baxter Healthcare Corporation v. Hospira, Inc. and
`Orion Corp [1:18-cv-00303]
`2016.10.14 Hospira’s Responses to Amneal’s Second Set of Interrogatories (Nos. 7-23) [1:15-cv-00697]
`
`2018.01.22 [119] Memorandum Opinion, Hospira v. Amneal Pharmaceuticals LLC [1:15-cv-00697]
`
`Plaintiff's Objections
`
`H
`
`H
`
`H
`
`H
`
`H
`
`H
`
`H
`H
`H
`H
`
`H
`H
`
`H
`H
`
`H
`
`H
`H
`F, H, P, R
`
`F, H, P, R
`
`F, H, P, R
`
`2016.02.03 Plaintiff’s Responses to Defendant’s First Set of Interrogatories to Plaintiff [Hospira v. Amneal
`1:15-cv-00697]
`Fresenius SE & Co. KGaA 2016 Annual Report
`Fresenius SE 2016 Annual Report
`SEC Hospira 2014 Form 10-K
`Who We Are; KRC Research [http://www.krcresearch.com/who-we-are/]
`Benzodiazepines: Overview and Use, Medically reviewed on May 4, 2014 by L. Anderson, PharmD,
`Drugs.com [https://www.drugs.com/article/benzodiazepines.html]
`
`F, H, P, R
`
`Au, F, H, P, R
`Au, F, H, P, R
`Au, F, H, P
`Au, F, H, P, R
`Au, F, H, P, R
`
`2
`
`

`

`DTX
`042
`
`043
`
`044
`
`045
`
`046
`
`047
`
`048
`
`049
`
`050
`
`051
`
`052
`
`053
`
`054
`
`055
`
`056
`
`057
`
`058
`
`059
`
`060
`
`061
`
`062
`
`Bates
`
`HOSPIRA_00500437-
`HOSPIRA_00500448
`HOSPIRA_00500909-
`HOSPIRA_00500919
`HOSPIRA_00501526-
`HOSPIRA_00501535
`HOSPIRA_00501604-
`HOSPIRA_00501615
`HOSPIRA_00501642-
`HOSPIRA_00501648
`HOSPIRA_00502190-
`HOSPIRA_00502191
`HOSPIRA_00502307-
`HOSPIRA_00502312
`HOSPIRA_00503082-
`HOSPIRA_00503084
`HOSPIRA_00503109-
`HOSPIRA_00503122
`HOSPIRA_00503414-
`HOSPIRA_00503419
`HOSPIRA_00503620-
`HOSPIRA_00503636
`HOSPIRA_00504913-
`HOSPIRA_00504916
`HOSPIRA_00504973-
`HOSPIRA_00504996
`HOSPIRA_00505199-
`HOSPIRA_00505201
`HOSPIRA_00505202-
`HOSPIRA_00505204
`HOSPIRA_00505394-
`HOSPIRA_00505401
`HOSPIRA_00505403-
`HOSPIRA_00505408
`HOSPIRA_00505897-
`HOSPIRA_00505902
`
`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 4 of 40 PageID #:3362
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Pfizer completes $15B acquisition of Hospira, Modern Healthcare, September 3, 2015,
`http://www.modernhealthcare.com/article/20150903/NEWS/309029996 accessed 5/14/2018]
`Pfizer Completes Acquisition of Hospira, Pfizer Press Release, September 3, 2015,
`https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_hospira
`
`Pharmedium, In-house Compounding vs Outsourcing, accessed April 10, 2018,
`https://www.pharmedium.com/wp-content/uploads/2018/01/in-house-compounding-vs-outsourcing-
`infographic-1.pdf
`Hospira Presentation. Precedex 20mL Premix Launch Update 1-30-15
`
`Hospira Presentation. Precedex ‘Front Foot’ Plan November 25, 2014
`
`Plaintiff's Objections
`Au, F, H, P, R
`
`Au, F, H, P, R
`
`F, H, P
`
`F, H, R, K
`
`F, H, P, R, K
`
`Hospira Presentation. Precedex 2015 Plan “Grow Premix by Selling Value” DRAFT (December 7, 2014)
`
`F, H, P, R, K
`
`Hospira Presentation. Precedex 2015 Plan “Grow Premix by Selling Value” DRAFT (December 3, 2014)
`
`F, H, P, R, K
`
`Hospira Presentation. Precedex Premix Contracting Strategy March, 2015
`
`Email Chain RE: 2016 Pfizer Injectables Targets [Redacted]
`
`Presentation. This is a premix only strategy.
`
`Hospira Presentation. Precedex Weekly EU - To Market Sales
`
`F, H, P, R, K
`
`F, H, P, R
`
`F, H, P, R, K
`
`F, H, P, R, K, X
`
`Hospira Presentation. moving. . .forward. . Today, Tomorrow, Together; Precedex Premix Launch Statistics F, H, P, R, K
`
`Hospira Presentation. Together We CAN; 2014 National Training Meeting; The Westin Kierland Resort Spa,
`Tucson, AZ February 3-6, 2014
`Hospira Presentation. Precedex Business Overview with Orion Pharma December 3, 2012
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`Email RE: ACCS Leadership News: September 8, 2014 Edition
`
`Hospira Presentation. 2014 2nd Half Comp Plan Proposed Changes (9/21/2014) [Redacted]
`
`Email Chain RE: FW: Updated Precedex Pricing
`
`Email Chain RE: Precedex (dexmedetomidine HCI lnj) Premix
`
`Spreadsheet. 626001_5000 Precedex Promotional & Conventions Committed & Uncomitted Spending, Q4
`2014 [Redacted]
`Hospira Presentation. Precedex/Propofol Deal Strategy (September, 2014)
`
`Spreadsheet. 626001_5000 Precedex Promotional & Conventions Uncommitted Spending, Q4 2014
`[Redacted]
`
`F, H, P, R
`
`F, H, P, R, K
`
`F, H, P, R
`
`F, H, P, R
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`3
`
`

`

`DTX
`063
`
`064
`
`065
`
`066
`
`067
`
`068
`
`069
`
`070
`
`071
`
`072
`
`073
`
`074
`
`075
`
`076
`
`077
`
`078
`
`079
`
`080
`
`081
`
`082
`
`083
`
`Bates
`HOSPIRA_00505964-
`HOSPIRA_00505966
`HOSPIRA_00506218-
`HOSPIRA_00506225
`HOSPIRA_00506235-
`HOSPIRA_00506240
`HOSPIRA_00542657-
`HOSPIRA_00542665
`HOSPIRA_00543493-
`HOSPIRA_00543521
`HOSPIRA_00545651-
`HOSPIRA_00545690
`HOSPIRA_00545779-
`HOSPIRA_00545790
`HOSPIRA_00546026-
`HOSPIRA_00546050
`HOSPIRA_00546053-
`HOSPIRA_00546108
`HOSPIRA_00563675-
`HOSPIRA_00563693
`HOSPIRA_00572975-
`HOSPIRA_00572982
`HOSPIRA_00586892-
`HOSPIRA_00586905
`HOSPIRA_00590241-
`HOSPIRA_00590271
`
`HOSPIRA_00647326 -
`HOSPIRA_00647327
`HOSPIRA_00659500-
`HOSPIRA_00659523
`HOSPIRA_00659598 -
`HOSPIRA_00659609
`HOSPIRA_00659626-
`HOSPIRA_00659716
`HOSPIRA_01101355-
`HOSPIRA_01101356
`HOSPIRA_01102036-
`HOSPIRA_01102043
`HOSPIRA_01103904-
`HOSPIRA_01103905
`HOSPIRA_02481292
`
`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 5 of 40 PageID #:3363
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Email RE: Precedex Price Decrease Margin Impact.xlsx
`
`Plaintiff's Objections
`F, H, P, R, K
`
`Spreadsheet. 626001_5000 Precedex Promotional & Conventions Committed & Uncomitted Spending, Q4
`2014 [Redacted]
`Spreadsheet. 626001_5000 Precedex Promotional & Conventions Uncommitted Spending, Q4 2014
`[Redacted]
`Hospira Presentation. moving. . .forward. . Today, Tomorrow, Together; 2013 Kickoff
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`Hospira Presentation. Precedex US Commercial Deep Dive August 2012 DRAFT [Redacted] [Color]
`
`F, H, P, R, K
`
`Hospira Presentation. Hospira & Proprietary Pharmaceuticals Historical Overview, Recent Events and
`Strategic Next Steps (Feb-6-2012) [Redacted]
`Hospira Presentation. CSO Update – Proprietary Platform January 18th 2012
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`R&D Submitted for Portfolio Review and Used as Basis for LRP Revenue Assumptions [Redacted]
`
`F, H, P, R, K
`
`R&D Submitted for Portfolio Review and Used as Basis for LRP Revenue Assumptions, including
`Scenario#2 plus“Product to be identified at a later date
`Presentation. Precedex Premix 20mL Targeting and Strategy 9/23/2014
`
`Hospira Presentation. Precedex PreMix LCM Protection Strategy [Redacted]
`
`Presentation. Precedex PreMix LCM Protection Strategy [Redacted]
`
`Presentation. Precedex PreMix LCM Protection Strategy, including Precedex PreMix Conversion
`Projections, Precedex Pricing Scenarios, and Potential Returns Precedex PreMix Launch Scenarios
`[Redacted]
`Email Chain RE: Precedex Overview_Pfizer_Mar6.pptx - need urgent review. Thanks [Redacted]
`
`Hospira Presentation. Business Review Meeting March 2015 [Redacted]
`
`Hospira Presentation. Precedex Premix; New Hire Training March 23, 2015
`
`Presentation. Dyloject and Precedex MAE Training; March 25, 2015 [Redacted]
`
`Email Chain RE: Turbocharge Growth Video: Hospira Obtains Six Months U.S. Pediatric Exclusivity and
`Premix Approval for Precedex
`Hospira, Inc. Fourth Quarter and Full-Year 2013 Conference Call 2014 Guidance February 12, 2014
`
`Presentation. Precedex Injection March 13, 2013 A Day That Will Go Down In History
`
`Presentation. Precedex Premix Price Premium Over Vial
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R, K
`
`F, H, P, R
`
`4
`
`

`

`DTX
`084
`
`Bates
`HOSPIRA_02482116
`
`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 6 of 40 PageID #:3364
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Presentation. Precedex Premix Price Premium Over Vial
`
`HOSPIRA_02484274
`
`Spreadsheet. precedex 2015 load for AP.xlsx [Document Produced Natively]
`
`2016.02.16 Second Expert Report of Mohan Rao, Ph.D. in Hospira v. EuroHealth [1:14-cv-487]
`
`Expert Report and Disclosure of Christopher P. Gerardi, Senior Managing Director FTI Consulting,
`Submitted March 20, 2017 in Hospira v. Amneal 1:15-CV-00697-RGA [Document Produced Natively]
`IMS Data Spreadsheet from the Expert Report of Andrew Carter [Eaches for January-April for 1992-1997 ]
`(Native Document)
`2016.09.29 Fresenius Kabi USA, LLC's Notice of Deposition of Robert A. Cedergren [1:16-cv-00651]
`
`Hospira Presentation. Precedex® Life Cycle Management Strategy Session [November 7, 2006]
`
`F, H, P, R, K
`
`HOSPIRA_02497377-
`HOSPIRA_02497450
`HOSPIRA_02498991-
`HOSPIRA_02499049
`
`HOSPIRA_00860898-
`HOSPIRA_00860992
`
`HOSPIRA_01138631-
`HOSPIRA_01138633
`
`Plaintiff's Objections
`F, H, P, R, K
`
`F, H, P, R, K
`
`Au, F, H, P, R
`
`F, H, P, R, K
`
`F, H, K, Y (assumed to be
`HOSPIRA_02498345)
`F, H, P, R
`
`F, R, H
`
`F, K, H, R, X
`
`Hospira Lab Book 00241 Project: 1638-04-02 pgs. 50-51; 56-57; 60-61
`
`HOSPIRA_00796788-
`HOSPIRA_00796852
`
`FDA Project Folder: Hospira Submissions 1165 Drug Number: 21-038 Drug Name: Precedex
`(Dexmedetomidine) dated 1/15/2008 through 4/9/2008
`
`HOSPIRA_00731616-
`HOSPIRA_00731623
`
`Hospira Global Pharma R&D D-040H Scientific Report Study No.: LF-220-R-027-08; Report Title: Filter
`Compatibility Study for Precedex Premix Injection 4 μg/mL; Revision: 1.0; Project Name/Number: Precedex
`Premix Injection
`HOSPIRA_00650082-
`Trissel, L.A. and Saenz, C.A., Compatibility Screening of Precedex: During Simulated Y·Site Administration
`HOSPIRA_00650085;
`with Other Drugs, Int J Pharm Compd Vol. 6 No. 3, May/June 2002 pp. 230-233 [Trissel]
`FK-DEXMED 0005851-
`FK-DEXMED 0005854
`
`F, H
`
`HOSPIRA_02481971-
`HOSPIRA_02481974
`HOSPIRA_02484274
`
`HOSPIRA_00552801-
`HOSPIRA_00552887
`HOSPIRA_02308691
`
`HOSPIRA_00500666-
`HOSPIRA_00500667
`
`2016.08.31 Amneal's Notice of Deposition of Hospira, Inc. Pursuant to Fed. R. Civ. P. 30(B)(6) [D.I. 60 in
`1:15-cv-00697]
`Email Chain RE: Access Pricing for OC Multispecialty Surgery Center
`
`Spreadsheet. LRP - 1 Competitor 1/2015 [.pdf attachment to Engels Dep. Ex. 4]
`
`BI Analyst Report – US October 2013 [Redacted]
`
`Graph. Dollars; Years Post Launch; Diprivan Precedex
`
`Graph. Net Sales
`
`H, X, R
`
`F, H, K, S
`
`F, H, K, S
`
`F, H, K, S
`
`X, V, S, NE, AU, H
`
`X, V, AU, H
`
`085
`
`086
`
`087
`
`088
`
`089
`
`090
`
`091
`
`092
`
`093
`
`094
`
`095
`
`096
`
`097
`
`098
`
`099
`
`100
`
`5
`
`

`

`Bates
`HOSPIRA_00502055-
`HOSPIRA_00502061
`HOSPIRA_00502448
`
`HOSPIRA_00594766-
`HOSPIRA_00594788
`HOSPIRA_00503329-
`HOSPIRA_00503369
`
`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 7 of 40 PageID #:3365
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Email Chain RE: Precedex DDD Slides - Week of 08/28/15 [Redacted]
`
`Plaintiff's Objections
`
`F, H
`
`Memorandum RE: Significant Events for May 2014; Precedex [Redacted]
`
`F, H, K, S
`
`Avenue Presentation. Precedex Sales Engagement Revised Report Prepared for: Hospira June 11, 2014
`
`F, H, K, S
`
`Hospira Presentation. Advancing Wellness™ ... through the right people and the right products (Jan. 24,
`2011)
`Appendix 1 Curriculum Vitae of Ivan T. Hofmann CPA, CFF, CLP
`
`F, H, K
`
`Appendix 2 List of Cases Pursuant to 26(a)(2)(B)
`
`Appendix 3 Listing of Documents Reviewed by Ivan T. Hofmann CPA, CFF, CLP
`
`HOSPIRA_00498257
`
`Price Reduction Precedex list number 1638-02 and Premix Supply Interruption
`
`HOSPIRA_00498258
`
`Precedex Premix Direct Only Program and Price Reduction Precedex list number 1638-02
`
`HOSPIRA_00498287
`
`Supply Interruption of Precedex premix formulations
`
`R, H
`
`R, H
`
`H, K
`
`H, K
`
`H, K
`
`HOSPIRA_00500291
`
`Precedex remains in good shape with May 25, MTD sales@ $9M [16/20 selling days]. Premix sales $8.4M F, H, K
`
`HOSPIRA_00500292
`
`Our charge is to maintain premix market share and margin
`
`HOSPIRA_00500426-
`HOSPIRA_00500436
`
`HOSPIRA_00500576
`
`HOSPIRA_00500658-
`HOSPIRA_00500659
`HOSPIRA_00500677-
`HOSPIRA_00500678
`HOSPIRA_00500931-
`HOSPIRA_00500934
`HOSPIRA_00500935-
`HOSPIRA_00500995
`HOSPIRA_00501633-
`HOSPIRA_00501634
`HOSPIRA_00501682-
`HOSPIRA_00501693
`HOSPIRA_00502049-
`HOSPIRA_00502051
`HOSPIRA_00502195-
`HOSPIRA_00502196
`
`Gal, A.R., Hospira, Mylan, Actavis: We Expect FDA Will Allow Section Eight Carve Out; Precedex at
`Material Near Term Risk, Bernstein Research, February 21, 2014 (Sanford C. Bernstein & Co., LLC, New
`York) [Gal]
`Presentation. HPG Precedex Premix Offer (HCA/CHI/TRINITY/CHSPSC)
`
`Email Chain RE: Good News. Attached is the form for the 20% launch stocking order for 20ml Precedex
`premix.
`Spreadsheet. Sales 2014 and 2015
`
`Hospira Presentation. Precedex Sales Performance Updated April 2015
`
`Spreadsheet. Sales 2000-2008
`
`Hospira Presentation. Proposed Time Line & Next Steps [2014 and 2015]
`
`Hospira Presentation. Precedex 20mL Premix Launch Update 1-23-15
`
`Email Chain RE: Precedex DDD Slides - Week of 08/28/15
`
`Email Chain RE: Precedex DDD Slides - Week of 08/07/15
`
`F, H, K
`
`F, H, K, S
`
`F, H, K
`
`F, H, K
`
`F, H, K, R
`
`F, H, K
`
`F, H, K, R
`
`F, H, K
`
`F, H, K
`
`F, H, K, X
`
`F, H, K, X
`
`DTX
`101
`
`102
`
`103
`
`104
`
`105
`
`106
`
`107
`
`108
`
`109
`
`110
`
`111
`
`112
`
`113
`
`114
`
`115
`
`116
`
`117
`
`118
`
`119
`
`120
`
`121
`
`122
`
`6
`
`

`

`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 8 of 40 PageID #:3366
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Email Chian RE: Precedex DDD Slides - Week of 08/07/15 [Redacted]
`
`Slides. 50ml Precedex Premix Unit ASP/Proposed Unit ASP and 100ml Precedex Premix Unit
`ASP/Proposed Unit ASP
`Slides. 50ml Precedex Premix Unit ASP/Proposed Unit ASP and 100ml Precedex Premix Unit
`ASP/Proposed Unit ASP
`Spreadsheet. Precedex [Redacted]
`
`Spreadsheet. Precedex 14-Aug through 15-0ct [Redacted]
`
`Customer Letter re: I regret to inform you that due to overwhelming demand, Hospira is experiencing a
`supply constraint for our PrecedexTM (dexmedetomidine HCI) injection premix formulations.
`Spreadsheet. Premix 2ML Vial Sum of Units Jan 2013 through Dec 2014
`
`Spreadsheet. Vial and Premix 15-Jan through 15-Sep [Redacted]
`
`Spreadsheet. Precedex [Redacted]
`
`Memorandum RE: Significant Events for March 2014 [Redacted]
`
`Memorandum RE: Significant Events for August 2014 [Redacted]
`
`Memorandum RE: Significant Events for May 2013 [Redacted]
`
`Plaintiff's Objections
`F, H, K, X
`
`F, H, K, X
`
`F, H, K, X
`
`F, H, K, X
`
`F, H, K, X
`
`F, H, K
`
`F, H, K, X
`
`F, H, K, X
`
`F, H, K, V
`
`F, H, K
`
`F, H, K
`
`F, H, K
`
`Hospira Interoffice Correspondence RE: Acute Care Proprietary Pharma Highlights for May 2014 [Redacted] F, H, K, S
`
`Hospira Interoffice Correspondence RE: Acute Care Proprietary Pharma Highlights for Oct. 2014 [Redacted] F, H, K
`
`Hospira Interoffice Correspondence RE: Acute Care Proprietary Pharma Highlights for Aug. 2014
`[Redacted]
`Spreadsheet. Precedex [Redacted]
`
`Presentation Slide. Proprietary Pharma strategy will focus on maximizing Precedex growth in 2014 and
`utilizing premix to preserve share and price throughout the LRP [Redacted]
`Hospira Presentation. Options to Manage Precedex Exclusivity 1.22.2014 [Redacted]
`
`Hospira Presentation. Precedex LOE Scenario Planning and Sensitivity 17 January 2014 [Redacted]
`
`Hospira Presentation. Precedex Premix Return to Market; August 7 [Redacted]
`
`Hospira Presentation. Proprietary Pharma Summary; United States [Redacted]
`
`Hospira Presentation. Precedex Vial Market
`
`Hospira Presentation. Brief Talking Points for ACCS/Precedex Team [Redacted]
`
`F, H, K, S
`
`F, H, K, V
`
`F, H, K, S
`
`F, H, K, S
`
`F, H, K, S
`
`F, H, K
`
`F, H, K
`
`F, H, K, M
`
`F, H, K
`
`DTX
`123
`
`124
`
`125
`
`126
`
`127
`
`128
`
`129
`
`130
`
`131
`
`132
`
`133
`
`134
`
`135
`
`136
`
`137
`
`138
`
`139
`
`140
`
`141
`
`142
`
`143
`
`144
`
`145
`
`Bates
`HOSPIRA_00502197-
`HOSPIRA_00502199
`HOSPIRA_00502263
`
`HOSPIRA_00502264
`
`HOSPIRA_00502270-
`HOSPIRA_00502271
`HOSPIRA_00502277
`
`HOSPIRA_00502282
`
`HOSPIRA_00502283-
`HOSPIRA_00502285
`HOSPIRA_00502290-
`HOSPIRA_00502293
`HOSPIRA_00502420-
`HOSPIRA_00502425
`HOSPIRA_00502435
`
`HOSPIRA_00502436-
`HOSPIRA_00502437
`HOSPIRA_00502458-
`HOSPIRA_00502459
`HOSPIRA_00502477
`
`HOSPIRA_00502480-
`HOSPIRA_00502481
`HOSPIRA_00502482-
`HOSPIRA_00502483
`HOSPIRA_00502579-
`HOSPIRA_00502599
`HOSPIRA_00502679
`
`HOSPIRA_00502709-
`HOSPIRA_00502719
`HOSPIRA_00502953-
`HOSPIRA_00502958
`HOSPIRA_00502987-
`HOSPIRA_00502998
`HOSPIRA_00503143-
`HOSPIRA_00503157
`HOSPIRA_00503188-
`HOSPIRA_00503194
`HOSPIRA_00503309-
`HOSPIRA_00503310
`
`7
`
`

`

`DTX
`146
`
`147
`
`148
`
`149
`
`150
`
`151
`
`152
`
`153
`
`154
`
`155
`
`156
`
`157
`
`158
`
`159
`
`160
`
`161
`
`162
`
`163
`
`164
`
`165
`
`166
`
`167
`
`Bates
`HOSPIRA_00503370-
`HOSPIRA_00503374
`HOSPIRA_00503375-
`HOSPIRA_00503387
`HOSPIRA_00503393-
`HOSPIRA_00503399
`HOSPIRA_00503407-
`HOSPIRA_00503413
`HOSPIRA_00504135-
`HOSPIRA_00504185
`HOSPIRA_00504533-
`HOSPIRA_00504609
`HOSPIRA_00504886-
`HOSPIRA_00504889
`HOSPIRA_00504899-
`HOSPIRA_00504900
`HOSPIRA_00505013-
`HOSPIRA_00505015
`HOSPIRA_00505078-
`HOSPIRA_00505080
`HOSPIRA_00505155-
`HOSPIRA_00505156
`HOSPIRA_00505176
`
`HOSPIRA_00505205-
`HOSPIRA_00505207
`HOSPIRA_00505217-
`HOSPIRA_00505218
`HOSPIRA_00505415-
`HOSPIRA_00505416
`HOSPIRA_00505417-
`HOSPIRA_00505418
`HOSPIRA_00505423-
`HOSPIRA_00505426
`HOSPIRA_00505431-
`HOSPIRA_00505432
`HOSPIRA_00505495-
`HOSPIRA_00505497
`
`HOSPIRA_00505566-
`HOSPIRA_00505567
`HOSPIRA_00505632-
`HOSPIRA_00505635
`HOSPIRA_00506011
`
`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 9 of 40 PageID #:3367
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Hospira Presentation. Precedex Life Cycle Management
`
`Plaintiff's Objections
`F, H, K, P
`
`Hospira Presentation. Evolution of the Precedex Sales Process [Redacted]
`
`Hospira Presentation. Premix Launch Price Strategy
`
`Hospira Presentation. Premix Launch Price Strategy [Redacted]
`
`Hospira Presentation. Update on Sedation Practices
`
`EPICC Precedex Promotional Program Business Rules; June 14, 2013
`
`Email Chain RE: FW: Precedex Premix Conversion Tracking (actual sales through 9-2-2014)
`
`Email Chain RE: vial to premix targets
`
`Email Chain RE: Precedex-Propofol Deal Strategy DAB 9-29.pptx
`
`Email Chain RE: JHP price update
`
`F, H, K
`
`F, H, K
`
`F, H, K
`
`F, H, K, R
`
`F, H, K, R
`
`F, H, K
`
`F, H, K
`
`F, H, K, S
`
`F, H, K, S
`
`Email Chain RE: FW: Precedex (dexmedetomidine HCI lnj) Premix
`
`F, H, K, S, V, P
`
`Email RE: IU Health network- Precedex Premix
`
`Email Chain RE: IU Health network- Precedex Premix
`
`Email Chain RE: New Pricing - Time to Rock!
`
`Email Chain RE: Account Statistics
`
`Email Chain RE: ACCS LEADERSHIP NEWS: OCTOBER 6, 2014 EDITION
`
`Email Chain RE: Precedex data review
`
`Email Chain RE: FW: premix stats as of today w new price
`
`Hospira Presentation. A Wholesaler Stocking Program may be necessary to preserve our ability to serve
`Premix customers in the month of September [Redacted]
`
`Email Chain RE: Premix Share Protection.ppt
`
`Spreadsheet. Precedex Share %
`
`Email RE: IU Health network- Precedex Premix
`
`F, H, K, P
`
`F, H, K, P
`
`F, H, K
`
`F, H, K, S
`
`F, H, K, R
`
`F, H, K, R
`
`F, H, K, R
`
`F, H, K
`
`F, H, K, X
`
`F, H, K, X, V
`
`F, H, K, S
`
`8
`
`

`

`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 10 of 40 PageID #:3368
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Email Chain RE: Precedex LOE Dashboard_DRAFT; Let me know what you think?
`
`Hospira Presentation. Precedex Sales [Redacted]
`
`Bates
`HOSPIRA_00506012-
`HOSPIRA_00506014
`HOSPIRA_00506163
`
`HOSPIRA_00506496
`
`Email Chain RE: Action Requested!
`
`HOSPIRA_00506585-
`HOSPIRA_00506586
`HOSPIRA_00506590-
`HOSPIRA_00506593
`HOSPIRA_00507656-
`HOSPIRA_00507661
`HOSPIRA_00509144-
`HOSPIRA_00509150
`HOSPIRA_00509834-
`HOSPIRA_00509852
`HOSPIRA_00511597-
`HOSPIRA_00511660
`HOSPIRA_00511859
`
`HOSPIRA_00512477-
`HOSPIRA_00512496
`HOSPIRA_00512713-
`HOSPIRA_00512715
`HOSPIRA_00512832-
`HOSPIRA_00512841
`HOSPIRA_00513584-
`HOSPIRA_00513695
`HOSPIRA_00514033-
`HOSPIRA_00514057
`HOSPIRA_00518823-
`HOSPIRA_00518908
`HOSPIRA_00519795-
`HOSPIRA_00519812
`HOSPIRA_00542443-
`HOSPIRA_00542480
`HOSPIRA_00542539
`
`HOSPIRA_00542541-
`HOSPIRA_00542545
`HOSPIRA_00542601-
`HOSPIRA_00542609
`HOSPIRA_00544948-
`HOSPIRA_00544955
`HOSPIRA_00549662-
`HOSPIRA_00550471
`
`Email Chain RE: Weekly Precedex data
`
`Spreadsheet. Precedex Share %
`
`Spreadsheet. 2014 DDD Reported Units; Equivalent Units; Reported Sales
`
`Spreadsheet. Precedex Vial Market Units
`
`Hospira Presentation. Strategic Selling
`
`Decision Development Inc. Presentation Presented to Hospira, Inc. June 2014 [Redacted]
`
`Email Chain RE: Precedex question
`
`Spreadsheet. 2014 AOP; Actual/LBE Sales Scenario 2; 2014 AOP Scenario 1; Demand Sales
`
`Spreadsheet. Precedex Sales in 000s
`
`Spreadsheet. Plan Sales; LBE Sales; Actual Sales; Demand Sales [2011-2014]
`
`Spreadsheet. Precedex Vial Prices (NSP) [10/14 through 03/15]
`
`Spreadsheet. United States Dollar Total Hospira Entities
`
`Spreadsheet. 01/01/14 - 12/01/15
`
`Hospira Presentation. Precedex Overview Jan 2014 to Mar 2015
`
`Spreadsheet. Precedex
`
`Hospira Interoffice Correspondence RE: Acute Care Proprietary Pharma Highlights for September 2011
`[Redacted]
`Precedex Exclusivity Management 1/29/2014
`
`Hospira Presentation. Precedex Price Escalation Impact
`
`Hospira Presentation. Precedex - Reigniting Growth in 2014
`
`Spreadsheet. Sandbox
`
`DTX
`168
`
`169
`
`170
`
`171
`
`172
`
`173
`
`174
`
`175
`
`176
`
`177
`
`178
`
`179
`
`180
`
`181
`
`182
`
`183
`
`184
`
`185
`
`186
`
`187
`
`188
`
`189
`
`190
`
`Plaintiff's Objections
`F, H, K, X
`
`F, H, K, X
`
`F, H, K, P
`
`F, H, K, S
`
`F, H, K, X, V
`
`F, H, K, V
`
`F, H, K
`
`F, H, K
`
`H
`
`F, H, K
`
`F, H, K, X, V
`
`F, H, R, V, K
`
`F, H, R, V, K
`
`F, H, K, V
`
`F, H, K, V
`
`F, H, K, V
`
`F, H, K
`
`F, H, K, V
`
`F, H, K, R
`
`F, H, K
`
`F, H, K
`
`F, H, K, R
`
`F, H, K, R, V
`
`9
`
`

`

`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 11 of 40 PageID #:3369
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`
`Hospira Presentation. Precedex Market Share
`
`Plaintiff's Objections
`F, H, K, S, X
`
`Hospira Presentation. BI Analyst Report – US; September 2013 [Redacted]
`
`Spreadsheet. Tot Eaches
`
`Hospira Presentation. BI Analyst Report – US; December 2013 [Redacted]
`
`Hospira Presentation. BI Analyst Report – US; February 2014 [Redacted]
`
`Hospira Presentation. Market Share Assessment - December 2014 [Redacted]
`
`Hospira Presentation. 2014-2018 LRP Discussion Precedex Assumptions
`
`Spreadsheet. Eaches 1994-2011
`
`Hospira Presentation. Design for Success 2015 Plan – Proprietary Franchise
`
`F, H, K, R
`
`F, H, K, R, V
`
`F, H, K, R
`
`F, H, K, R
`
`F, H, K, R
`
`F, H, K, R, S
`
`F, H, K, R
`
`F, H, K, R
`
`Spreadsheet. ALL CHANNEL Injectable Report - US NonRetail Market [Source: IMS Health National Sales
`Perspective December 2010]
`
`F, H, K
`
`Spreadsheet. 2008 and 2012 Precedex Diprivan Benzodiazepines [Midazolam lnj and Lorazepam lnj]
`
`F, H, K, R
`
`Hospira Product Development Concept Proposal Precedex Line Extension September 22, 2006 [Redacted] F, H, K
`
`Precedex Competitor Analysis [Data source IMS DDD data week ending 1/30/15]
`
`HOSPIRA_00647289
`
`Email RE: 2014 Precedex pricing
`
`DTX
`191
`
`192
`
`193
`
`194
`
`195
`
`196
`
`197
`
`198
`
`199
`
`200
`
`201
`
`202
`
`203
`
`204
`
`205
`
`206
`
`207
`
`208
`
`209
`
`210
`
`211
`
`212
`
`Bates
`HOSPIRA_00551546-
`HOSPIRA_00551547
`HOSPIRA_00552691-
`HOSPIRA_00552775
`HOSPIRA_00553182-
`HOSPIRA_00553682
`HOSPIRA_00554108-
`HOSPIRA_00554194
`HOSPIRA_00554286-
`HOSPIRA_00554372
`HOSPIRA_00561037-
`HOSPIRA_00561056
`HOSPIRA_00565935-
`HOSPIRA_00565945
`HOSPIRA_00595412-
`HOSPIRA_00595858
`HOSPIRA_00604005-
`HOSPIRA_00604030
`HOSPIRA_00604443-
`HOSPIRA_00604595
`
`HOSPIRA_00636558-
`HOSPIRA_00636559
`HOSPIRA_00642981-
`HOSPIRA_00642988
`HOSPIRA_00647266
`
`HOSPIRA_00647293-
`HOSPIRA_00647325
`HOSPIRA_00651032-
`HOSPIRA_00651033
`HOSPIRA_00651924-
`HOSPIRA_00651944
`HOSPIRA_00658113-
`HOSPIRA_00658121
`HOSPIRA_00659096-
`HOSPIRA_00659104
`HOSPIRA_00659303-
`HOSPIRA_00659304
`HOSPIRA_00659317-
`HOSPIRA_00659325
`HOSPIRA_00659404-
`HOSPIRA_00659421
`
`Spreadsheet. 2014 Precedex Pricing
`
`Presentation. Precedex Market Share
`
`Presentation. Precedex PreMix LCM Protection Strategy [Redacted]
`
`Hospira Presentation. All Manufacturers Equivalent Unit Market Share 4 Week Rolling Average [Data
`Source: IMS DDD Data reported 12/10/14]
`Hospira Presentation. Total Market Equivalent Unit Trend 4 Week Rolling Average [Data Source: IMS DDD
`Data reported 01/28/15]
`Spreadsheet. Precedex Competitor Analysis [Redacted]
`
`Hospira Presentation. Total Market Equivalent Unit Trend 4 Week Rolling Average [Data Source: IMS DDD
`Data reported 02/25/15]
`Hospira Presentation. Precedex Overview Jan 2014 to Mar 2015 (Mar. 6 2015)
`
`F, H, K
`
`F, H, K
`
`F, H, K, X
`
`F, H, K, P
`
`F, H, K
`
`F, H, K, S
`
`F, H, K
`
`F, H, K
`
`F, H, K
`
`F, H, K
`
`10
`
`

`

`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 12 of 40 PageID #:3370
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`Hospira Presentation. All Manufacturers Equivalent Unit Market Share 4 Week Rolling Average [Data
`Source: IMS DDD Data reported 04/29/15]
`Hospira Presentation. Precedex Premix; New Hire Training; March 23, 2015
`
`Hospira Presentation. All Manufacturers Equivalent Unit Market Share 4 Week Rolling Average [Data
`Source: IMS DDD Data reported 07/01/15]
`Decision Development Inc. Presentation. Precedex® LT Sedation Qualitative Market Research Presented to
`Hospira, Inc. May 2008
`Precedex Line Extension Meeting Minutes 11/4/2011
`
`Presentation. Precedex 3.2 LBE [Redacted]
`
`Email RE: Precedex Premix conversion tracking (actual sales through 6/30/20
`
`Hospira Global Post Approval Regulatory Strategy for Precedex (Dexmedetomidine Hydrochloride Injection)
`Line Extension - Qualification of 4 mcg/mL Presentations [Revision 1.0]
`Email Chain RE: Precedex Flip top seals
`
`Hospira Submission Notification Precedex Line Extension – Premix September 29, 2009
`
`Hospira Presentation. Above and Beyond; 2006 Sales Tactics and Tools
`
`Memorandum RE: Significant Events for Jan 2010
`
`Plaintiff's Objections
`F, H, K
`
`F, H, K, S
`
`F, H, K
`
`H
`
`F, H, K, R
`
`F, H, K, S, V, P
`
`F, H, K, V
`
`F, K
`
`F, H, R, K
`
`F, H, K
`
`F, H, K, R
`
`F, H, K, R
`
`When Choosing An IV Sedative The Question Isn’t Which One Will Work. . .But How Well Suited Is It?
`
`F, H, K, R
`
`Spreadsheet. IMS Injectable Database Report - 4th Quarter 2003
`
`Spreadsheet. Medication Cost Data
`
`Spreadsheet. Precedex 2008-2013 Commercial P&L Apr, 2008
`
`Hospira Presentation. Precedex US Sales Performance (000's)
`
`PrimeDEX® (dexmedetomidine) CONCEPT RESEARCH, A QUALITATIVE STUDY prepared for Abbott
`Laboratories Hospital Products Division November, 1999; conducted by Decision Development Inc.
`
`F, H, K, R, V
`
`F, H, K, R, V
`
`F, H, K
`
`F, H, K, R
`
`F, H, P, R
`
`Bates
`HOSPIRA_00660214-
`HOSPIRA_00660222
`HOSPIRA_00660505-
`HOSPIRA_00660516
`HOSPIRA_00660524-
`HOSPIRA_00660532
`HOSPIRA_00661205-
`HOSPIRA_00661233
`HOSPIRA_00669972-
`HOSPIRA_00669975
`HOSPIRA_00730441-
`HOSPIRA_00730443
`HOSPIRA_00730444
`
`HOSPIRA_00791479-
`HOSPIRA_00791494
`HOSPIRA_00858387-
`HOSPIRA_00858389
`HOSPIRA_00863299-
`HOSPIRA_00863301
`HOSPIRA_01261480-
`HOSPIRA_01261532
`HOSPIRA_01354146-
`HOSPIRA_01354147
`HOSPIRA_01719912-
`HOSPIRA_01719914
`HOSPIRA_01725980-
`HOSPIRA_01726497
`HOSPIRA_01736417-
`HOSPIRA_01736428
`HOSPIRA_01824400-
`HOSPIRA_01824512
`HOSPIRA_01825525-
`HOSPIRA_01825529
`HOSPIRA_01997908-
`HOSPIRA_01997963
`
`HOSPIRA_01997968-
`HOSPIRA_01997982
`
`PreceDEX® (dexmedetomidine) DETAIL AID RESEARCH, A QUALITATIVE STUDY prepared for Abbott
`Laboratories Hospital Products Division December, 1999; conducted by Decision Development Inc.
`
`F, H, P, R
`
`HOSPIRA_01998011-
`HOSPIRA_01998026
`HOSPIRA_01998060-
`HOSPIRA_01998081
`HOSPIRA_02012023-
`HOSPIRA_02012099
`
`PRECEDEX™ Qualitative Research Final Summary Report, prepared for Abbott Laboratories Hospital
`Products Division January, 2000; conducted by Decision Development Inc.
`PRECEDEX AWARENESS AND USAGE STUDY - QUALITATIVE STUDY- prepared for Goble &
`Associates January 2002; conducted by Decision Development Inc.
`Spreadsheet. US Hospital Specialty Pharma
`
`F, H, P, R
`
`F, H, P, R
`
`F, H, P, R
`
`DTX
`213
`
`214
`
`215
`
`216
`
`217
`
`218
`
`219
`
`220
`
`221
`
`222
`
`223
`
`224
`
`225
`
`226
`
`227
`
`228
`
`229
`
`230
`
`231
`
`232
`
`233
`
`234
`
`11
`
`

`

`Case: 1:16-cv-00651 Document #: 114-5 Filed: 06/25/18 Page 13 of 40 PageID #:3371
`Hospira v. Fresenius Kabi USA, LLC C.A. No. 1:16-cv-00651; 1:17-cv-07903 (ND IL )
`Freseinus Kabi’s Exhibit List
`Description
`
`Spreadsheet. Eaches 1994-2010
`
`Spreadsheet. Precedex Market 2002 Plan: Dollar Acquisitions Market/Segment/Shares (Gross Dollar
`Acquisitions - 000's)
`Spreadsh